-
1. Clinical Utility of Comprehensive Genomic Profiling Tests for Advanced or Metastatic Solid Tumor in Clinical Practice. Cancer Sci (Sep 14 2022).https://dx.doi.org/10.1111/cas.15586.
Ida, H., T. Koyama, T. Mizuno, K. Sunami, T. Kubo, K. Sudo, K. Tao, M. Hirata, K. Yonemori, K. Kato, T. Okusaka, Y. Ohe, Y. Matsui, N. Yamazaki, C. Ogawa, A. Kawai, Y. Narita, M. Esaki, and N. Yamamoto.
-
2. Chronological Improvement in Precision Oncology Implementation in Japan. Cancer Sci (Aug 17 2022). https://dx.doi.org/10.1111/cas.15517.
Sunami, K., Y. Naito, K. Komine, T. Amano, D. Ennishi, M. Imai, H. Kage, M. Kanai, H. Kenmotsu, T. Koyama, T. Maeda, S. Morita, D. Sakai, S. Kohsaka, K. Tsuchihara, Y. Saigusa, and T. Yoshino.
-
3. Phase I/Iia Trial of Bms-986148, an Anti-Mesothelin Antibody-Drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.Clin Cancer Res 28, no. 1 (Jan 1 2022): 95-105. https://dx.doi.org/10.1158/1078-0432.Ccr-21-1181.
Rottey, S., J. Clarke, K. Aung, J. P. Machiels, B. Markman, K. M. Heinhuis, M. Millward, M. Lolkema, S. P. Patel, P. de Souza, M. Duca, G. Curigliano, A. Santoro, T. Koyama, M. Brown, H. Vezina, C. He, and Q. S. Chu.
-
4. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-Lf) in Japanese Patients with Advanced Solid Tumors. Clin Cancer Res 28, no. 9 (May 2 2022): 1783-91. https://dx.doi.org/10.1158/1078-0432.Ccr-21-3518.
Sato, J., T. Shimizu, T. Koyama, S. Iwasa, A. Shimomura, S. Kondo, S. Kitano, K. Yonemori, Y. Fujiwara, K. Tamura, T. Suzuki, T. Takase, R. Nagai, K. Yamaguchi, T. Semba, Z. M. Zhao, M. Ren, and N. Yamamoto.
-
5. Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors.Cancer Sci (Jul 25 2022). https://dx.doi.org/10.1111/cas.15504.
Imai, M., Y. Nakamura, K. Sunami, H. Kage, K. Komine, T. Koyama, T. Amano, D. Ennishi, M. Kanai, H. Kenmotsu, T. Maeda, S. Morita, D. Sakai, H. Bando, A. Makiyama, T. Suzuki, M. Hirata, S. Kohsaka, K. Tsuchihara, Y. Naito, and T. Yoshino.
-
6. Yamamoto.Practical Consideration for Successful Sequential Tumor Biopsies in First-in-Human Trials. Invest New Drugs 40, no. 4 (Aug 2022): 841-49. https://dx.doi.org/10.1007/s10637-022-01236-4.
Koyama, T., T. Shimizu, J. Sato, Y. Katsuya, S. Iwasa, S. Kondo, T. Yoshida, K. Sudo, M. Nishino, Y. Takiguchi, K. Yonemori, and N.
-
7. Yamamoto.Study Protocol for Ncch1908 (Upfront-Trial): A Prospective Clinical Trial to Evaluate the Feasibility and Utility of Comprehensive Genomic Profiling Prior to the Initial Systemic Treatment in Advanced Solid Tumour Patients.Jpn J Clin Oncol 51, no. 12 (Dec 1 2021): 1757-60. https://dx.doi.org/10.1093/jjco/hyab159.
Mizuno, T., T. Yoshida, K. Sunami, T. Koyama, N. Okita, T. Kubo, K. Sudo, T. Shimoi, H. Ueno, E. Saito, K. Katanoda, T. Shibata, K. Yonemori, T. Okusaka, N. Boku, Y. Ohe, Y. Hiroshima, M. Ueno, Y. Kuboki, T. Doi, K. Nakamura, T. Kohno, Y. Yatabe, and N.
-
8. Comprehensive Functional Evaluation of Variants of Fibroblast Growth Factor Receptor Genes in Cancer.NPJ Precis Oncol 5, no. 1 (Jul 16 2021): 66. https://dx.doi.org/10.1038/s41698-021-00204-0.
Nakamura, I. T., S. Kohsaka, M. Ikegami, H. Ikeuchi, T. Ueno, K. Li, T. S. Beyett, T. Koyama, T. Shimizu, N. Yamamoto, F. Takahashi, K. Takahashi, M. J. Eck, and H. Mano.
-
9. First-in-Human Phase 1 Study of Morab-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-Α-Positive Advanced Solid Tumors.Clin Cancer Res 27, no. 14 (Jul 15 2021): 3905-15. https://dx.doi.org/10.1158/1078-0432.Ccr-20-4740.
Shimizu, T., Y. Fujiwara, K. Yonemori, T. Koyama, J. Sato, K. Tamura, A. Shimomura, H. Ikezawa, M. Nomoto, K. Furuuchi, R. Nakajima, T. Miura, and N. Yamamoto.
-
10. Correction To: The Initial Assessment of Expert Panel Performance in Core Hospitals for Cancer Genomic Medicine in Japan. Int J Clin Oncol 26, no. 5 (May 2021): 1007. https://dx.doi.org/10.1007/s10147-021-01897-w.
Sunami, K., Y. Naito, E. Aimono, T. Amano, D. Ennishi, H. Kage, M. Kanai, K. Komine, T. Koyama, T. Maeda, S. Morita, D. Sakai, S. Kohsaka, K. Tsuchihara, and T. Yoshino.
-
11. The Initial Assessment of Expert Panel Performance in Core Hospitals for Cancer Genomic Medicine in Japan. Int J Clin Oncol 26, no. 3 (Mar 2021): 443-49. https://dx.doi.org/10.1007/s10147-020-01844-1.
Sunami, K., Y. Naito, E. Aimono, T. Amano, D. Ennishi, H. Kage, M. Kanai, K. Komine, T. Koyama, T. Maeda, S. Morita, D. Sakai, S. Kohsaka, K. Tsuchihara, and T. Yoshino.
-
12. First-in-Human Phase I Study of E7090, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors. Cancer Sci 111, no. 2 (Feb 2020): 571-79. https://dx.doi.org/10.1111/cas.14265.
Koyama, T., T. Shimizu, S. Iwasa, Y. Fujiwara, S. Kondo, S. Kitano, K. Yonemori, A. Shimomura, S. Iizumi, T. Sasaki, J. Furuse, and N. Yamamoto.
-
13. Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients with Hepatocellular Carcinoma in Phase I Clinical Trials. Front Oncol 9 (2019): 301. https://dx.doi.org/10.3389/fonc.2019.00301.
Koyama, T., S. Kondo, T. Shimizu, Y. Fujiwara, C. Morizane, Y. Sakamoto, T. Okusaka, and N. Yamamoto.
-
14. Feasibility and Utility of a Panel Testing for 114 Cancer-Associated Genes in a Clinical Setting: A Hospital-Based Study. Cancer Sci 110, no. 4 (Apr 2019): 1480-90. https://dx.doi.org/10.1111/cas.13969.
Sunami, K., H. Ichikawa, T. Kubo, M. Kato, Y. Fujiwara, A. Shimomura, T. Koyama, H. Kakishima, M. Kitami, H. Matsushita, E. Furukawa, D. Narushima, M. Nagai, H. Taniguchi, N. Motoi, S. Sekine, A. Maeshima, T. Mori, R. Watanabe, M. Yoshida, A. Yoshida, H. Yoshida, K. Satomi, A. Sukeda, T. Hashimoto, T. Shimizu, S. Iwasa, K. Yonemori, K. Kato, C. Morizane, C. Ogawa, N. Tanabe, K. Sugano, N. Hiraoka, K. Tamura, T. Yoshida, Y. Fujiwara, A. Ochiai, N. Yamamoto, and T. Kohno.